drugset
drugset / Trial / NCT00836927

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

NCT00836927 ↗

Phase 2 Terminated 7 enrolled Merck Sharp & Dohme LLC Ariad Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To describe the long-term safety of deforolimus (ridaforolimus, MK-8669) in participants for whom a clinical benefit has been established in a prior parent trial (MK-8669-013, NCT00060645; MK-8669-016, NCT00112372; and MK-8669-028, NCT00704054) with deforolimus and/or in those who remain in long-term follow-up.

Timeline

Start
2009-02-01
Primary completion
2017-04-03
Completion
2018-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ridaforolimus Small molecule 10 mg Oral
Subject ridaforolimus Small molecule 20 mg Oral
Subject ridaforolimus Small molecule 30 mg Oral
Subject ridaforolimus Small molecule 40 mg Oral

Indications

No indication recorded.